Introduction {#s0005}
============

Breast cancer is the fourth most common cancer in Japanese women and accounted for an estimated 9806 deaths in 2003 [@bb0005]. Although there have been major improvements in oncologic treatments, breast cancers frequently recur after primary treatment, and following recurrence, these cancers are incurable. Treatment options for inoperable advanced, metastatic, or recurrent breast cancer includes hormone therapy, anti-human epidermal receptor type 2 (HER2) therapy, and chemotherapy, depending on results from pathological examination of the tumor specimens.

Anthracycline and taxane are the major cytotoxic agents representing highly efficacious chemotherapeutics. A chemotherapy regimen including an anthracycline or taxane agent can also be administered as part of first- or second-line chemotherapy for inoperable advanced, metastatic, or recurrent breast cancer; however, these agents are frequently not selected for first-or second-line chemotherapy, because these drugs might have been administered as neoadjuvant or adjuvant chemotherapy during primary treatment. Other cytotoxic agents, such as eribulin, capecitabine, vinorelbine, and gemcitabine, can be selected for systemic chemotherapy in patients previously treated with anthracycline and taxane agents [@bb0010]. Eribulin is a non-taxane microtubule inhibitor reported to improve overall survival (OS) of patients with metastatic breast cancer previously treated with anthracycline and taxane and relative to treatment with physicians' choice according to findings from the EMBRACE trial [@bb0015]. Since report of the EMBRACE results, eribulin has been considered a standard of care for this population of breast cancer patients and was approved for use by the Food and Drug Administration (FDA) in the United States and the Pharmaceuticals and Medical Devices Agency in Japan in 2010.

In breast cancer, hormone-receptor-negative, HER2-negative breast cancer is referred to as triple-negative breast cancer (TNBC) and estimated to account for 10% to 20% of all breast cancers. TNBC occurs at a younger age and with a higher tumor grade, highly proliferative tumor characteristics, and poor survival as compared with other types of breast cancers. The treatment options for this type of breast cancer are limited to chemotherapy; therefore, there is a large unmet medical need for new treatment strategies for patients with TNBC [@bb0020], [@bb0025].

Olaparib (AZD2281) is a potent polyadenosine 5′-diphosphoribose (poly-ADP ribose) polymerase (PARP)-1, −2, and− 3 inhibitor currently being developed as an oral therapy both as monotherapy, including tumor maintenance, and in combination with other anticancer agents. PARP inhibition is a novel approach for targeting tumors with deficiencies in DNA-repair mechanisms. PARP enzymes are essential for repairing DNA single-strand breaks (SSBs), and inhibiting PARPs leads to the persistence of SSBs, which are then converted to more serious DNA double-strand breaks (DSBs) during DNA replication. During the process of cell division, DSBs can be efficiently repaired in normal cells through homologous recombination repair (HRR); however, tumors with HRR deficiencies (HRD), such as serous ovarian cancers and breast cancer, cannot accurately repair the DNA damage, resulting in accumulating damaged DNA becoming potentially lethal to tumor cells. In such tumor types, olaparib might potentially serve as an efficacious and less toxic cancer treatment as compared with currently available chemotherapy regimens.

Olaparib inhibits selected tumor-cell lines *in vitro* and in xenograft and primary explant models, as well as in genetic *breast cancer susceptibility gene* (*BRCA*) knockout models, either as standalone treatment or in combination with established chemotherapeutics. Cells deficient in HRR factors, notably *BRCA1/2*, are particularly sensitive to olaparib treatment. PARP inhibitors, such as olaparib, might also enhance the DNA-damaging effects of other chemotherapy agents [@bb0030], [@bb0035], [@bb0040], [@bb0045]. *BRCA1*-related breast cancer accounts for 5% of all breast cancers [@bb0050]. Although \>50% of *BRCA1*-mutation carriers have TNBC according to pathological analyses [@bb0055], [@bb0060], patients with TNBC do not necessarily harbor *BRCA1* mutations. However, previous studies report that TNBC patients harboring wild-type *BRCA1* frequently exhibit downregulated *BRCA1* expression or alterations in BRCA1 function, which might occur through methylation of the *BRCA1* promoter or overexpression of the protein that normally regulates *BRCA1* expression [@bb0065], [@bb0070], [@bb0075], [@bb0080].

Mutations in numerous HRR genes lead to phenotypes similar to those associated with mutated *BRCA1/2*, a situation called BRCAness. Previous studies report an elevated risk for cancer development associated with HRR deficiencies, such those associated with as *RAD51*, *BRIP1*, *PALB2*, and *FANCA* mutation. Actually, 50% of high-grade serous ovarian cancers involve at least one HRR-modulating gene alteration. In a clinical trial for high-grade serous ovarian carcinoma (HGS-OvCa), olaparib maintenance therapy doubled the progression-free survival (PFS) of patients with *BRCA1/2* germline-mutation, platinum-sensitive HGS-OvCa [@bb0085]. Additionally, in a phase II study, olaparib showed efficacy as maintenance therapy for platinum-sensitive relapsed HGS-OvCa patients, regardless of germline *BRCA1/2* status [@bb0090]. Moreover, maintenance therapy involving niraparib and rucaparib showed a significant response and prolonged PFS for patients with HGS-OvCa, regardless of *BRCA1/2* status but especially in those with non- *BRCA1/2* -related HRR deficiency [@bb0095], [@bb0100]. However, In TNBC, the clinical significance of HRD to PARP inhibition has been not evaluated.

Here, we conducted a phase I/II clinical trial (EO study) to evaluate the efficacy of eribulin combined with the tablet form of olaparib for TNBC patients. We enrolled 24 patients in phase I, and one patient in the first cohort experienced dose-limiting toxicity (DLT). The recommended phase II dose (RP2D) was established as the approved dose for both drugs (olaparib: 300 mg twice daily with eribulin 1.4 mg/m^2^). All 24 patients received RP2D in phase II, with the median number of courses administered in phase II at 5.5 (range: 1--28). For the 22 evaluable patients, the response rate was 18.2% \[complete response (CR): 0; partial response (PR): 4; 95% confidence interval (CI): 6.5--36.9)\]. Median PFS and OS were 4.2 (95% CI: 3.0--7.4) and 14.5 (95% CI: 4.8--22.0), respectively [@bb0105].

We hypothesized that *BRCA* mutations and HRR-related gene alterations might contribute to the efficacy results obtained from the EO study. Therefore, we identified the existence of mutations in HRR-related genes and *BRCA1/2* and evaluated their association with patient response to eribulin/olaparib combination therapy among the participants in the EO study.

Materials and Methods {#s0010}
=====================

Patients {#s0015}
--------

The study was approved by the institutional review board of the National Cancer Center, Tokyo (2012-236), and complied with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from each patient. All patients had participated in the phase I/II EO study. The EO study is an open-label, non-randomized, multi-center, dose-escalation study of olaparib in combination with eribulin mesylate aimed to assess safety, tolerability, and efficacy in patients with recurrent or metastatic TNBC. The EO study is a multi-institutional study that includes seven sites in Japan.

Tissue specimens from metastatic/primary sites were obtained at the time of surgery or biopsy from each site. Germline *BRCA* mutations were analyzed in patients who had consented to provide two blood samples for confirmatory germline *BRCA1/2*-mutation testing using the Myriad Genetics BRCA test (Myriad BRACAnalysis; Myriad Genetics, Salt Lake City, UT, USA). Patients with a known *BRCA1/2* mutation were analyzed on the basis of this information.

Gene Analysis {#s0020}
-------------

Archival tissue samples were examined for gene alterations using a Foundation Medicine, Inc. (FMI) gene panel. Pathogenic or likely pathogenic gene alterations were extracted from all detected gene alterations using the FMI data dictionary. This dictionary uses the COSMIC database, relevant literature, and internal evidence to determine the reportable status of an alteration. We chose previously defined HRR-related genes, including *BRCA1, BRCA2, PALB2, FANCA, FANCI, FANCL, FANCC, RAD50, RAD51, RAD51C, RAD54L, ATM, ATR, CHEK1,* and *CHEK2* [@bb0110]. Correlation between the presence of HRR-related gene mutation and patient cancer response to the combination therapy was determined.

Immunohistochemistry {#s0025}
--------------------

We examined epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6), (BRCA1/ 2, vimentin, zinc finger E-box binding homeobox 1 (ZEB1), and E-cadherin. Primary antibodies are presented in [Table S1](#ec0005){ref-type="supplementary-material"}. For all antibodies, except that for ZEB1, antigens were retrieved with citrate buffer treatment at 121 °C for 10 min. The Envision method was used for the secondary antibody reaction, and diaminobenzidine tetrahydrochloride was used for the peroxidase reaction [@bb0115]. For the ZEB1 antibody, antigen was retrieved with Target Retrieval solution PH9 (TRS9; DAKO; Agilent Technologies, Santa Clara, CA, USA) at 98 °C for 40 min, and Histofine Simple Stain MAX-PO(G) (Nichirei, Tokyo, Japan) was used for the secondary antibody reaction.

For BRCA1 and BRCA2, the proportion of positive cells (score: 0--5) and staining intensity (score: 0--3) were considered [@bb0120], and the expression was regarded as positive when the sum of these scores was \>2. In cases of a score of 2 with weak-internal positive staining, expression was regarded as equivocal. Cytoplasmic and/or membranous immunoreactive staining was regarded positive if ≥10% of the cells were stained, regardless of intensity. Moderate-to-strong membranous/cytoplasmic staining (2+ or 3+, respectively) in ≥10% of tumor cells was regarded as positive for EGFR only. Immunohistochemistry (IHC) results were independently evaluated by two researchers (A.S. and M.Y.) without knowledge of the clinical characteristics ([Figure S1](#f0025){ref-type="graphic"}).

Results {#s0030}
=======

Gene Expression, Amplification, and Homologous Deletion {#s0035}
-------------------------------------------------------

A total of 32 tissue specimens were collected, with 19 samples collected from the phase I trial and 13 samples from the phase II trial. Seventeen patients were treated at the recommended dose. [Figure 1](#f0005){ref-type="fig"} shows the landscape of the gene mutations.Figure 1**The landscape of gene alterations in patients treated with the combination therapy of eribulin and olaparib.** Red color indicates pathogenic mutations, orange color indicates likely pathogenic mutations, and yellow color indicates variants of uncertain significance. Genes without any alterations are not showed in this figure.RECIST, response evaluation criteria in solid tumor; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.Figure 1

Thirty-three gene mutations were detected in the TNBC specimens. The most frequent nonsynonymous mutations were in *TP53* (n = 27; 84.4%), *PIK3CA* (n = 7; 21.9%), *BRCA1* (n = 5; 15.6%), *MLL3* (n = 5; 15.6%), *AKT1* (n = 4; 12.5%), *NF1* (n = 3; 9.4%), *NFKKBIA* (n = 3; 9.4%), *CHD1* (n = 2; 6.3%), *RB1* (n = 2; 6.3%), and *PTEN* (n = 2; 6.3%) ([Figure 2](#f0010){ref-type="fig"}*A*). Detection of gene amplifications revealed the most frequent for *MYC* (n = 6; 18.8%), *EGFR* (n = 2; 6.3%), *KDM5A* (n = 2; 6.3%), *LYN* (n = 2; 6.3%), and *CDK6* (n = 2; 6.3%) ([Figure 2](#f0010){ref-type="fig"}*B*). Eight homozygous deletions were detected, with the most frequent being the loss of *PTEN* (n = 4; 12.5%). As shown in [Figure 2](#f0010){ref-type="fig"}*C*, other frequently observed homozygous deletions included loss of *STK11* (n = 2; 6.3%), *TP53* (n = 2; 6.3%), and *CDKN2A* (n = 2; 6.3%). Additionally, we detected 10 gene rearrangements, and HRD, including *BRCA1/2* mutations, were observed in nine patients ([Figure 1](#f0005){ref-type="fig"}).Figure 2Gene mutations, amplifications, and homozygous deletions in patients treated with combination therapy of eribulin and olaparib.Figure 2

Response was evaluable in 29 patients. CR was observed in one patient (3.4%), and PR was observed in seven (24.1%). The ORR for CR and PR and the clinical benefit rate (CBR) for CR, PR, and stable disease were 34.5% and 75.9%, respectively. The ORRs in patients with HRD and without HRD were 33.3% and 40%, respectively (*P* = .732), and those for patients with and without somatic *BRCA* mutation were 60% and 33.3%, respectively (*P* = .264) ([Table 1](#t0005){ref-type="table"}). ORR was numerically higher in the somatic *BRCA*-mutation group, although the difference was not statistically significant.Table 1Response to eribulin/olaparib combination treatment by patients with somatic BRCA mutation or homologous recombination repair deficiency (HRD)Table 1Objective response (%)*P*HRDn = 29pos (n = 9)3 (33.3%).732neg (n = 20)8 (40%)Somatic BRCA Mutationn = 29pos (n = 5)3 (60%).264neg (n = 24)8 (33.3%)[^1][^2]

The response rate in patients with germline *BRCA1/2* mutation (n = 5) was 40% (CR in 0 patients and PR in 2 patients). No PD was observed. This rate was higher than that in the overall population.

Immunohistochemistry {#s0040}
--------------------

IHC analysis of the evaluable specimens revealed that BRCA1 was positive in 58.6% of the specimens, BRCA2 was positive in 53.6%, EGFR was positive in 42.9%, CK5/6 was positive in 13.8%, E-cadherin was positive in 10.7%, ZEB1 was positive in 10.7%, and vimentin was positive in 67.9%. There was no correlation between the IHC status of any of the markers evaluated and response to eribulin/olaparib combination therapy ([Table 2](#t0010){ref-type="table"}).Table 2Response to eribulin/olaparib combination treatment by patients relative to immunohistochemistry statusTable 2RespondersNon-responders*P* valueBRCA1\
n = 29pos17 (58.6%)512.260neg12 (41.4%)66BRCA2\
n = 28pos15 (53.6%)69.934neg13 (46.4%)58EGFR\
n = 28pos12 (42.9%)48.576neg16 (57.1%)79CK5/6\
n = 29pos4 (13.8%)22.592neg25 (86.2%)916E-cadherin\
n = 28pos3 (10.7%)03.140neg25 (89.3%)1114ZEB1\
n = 28pos3 (10.7%)21.304neg25 (89.3%)916Vimentin\
n = 28pos19 (67.9%)811.657neg9 (32.1%)36[^3][^4]

Survival Analysis According to Gene Alteration and IHC Status {#s0045}
-------------------------------------------------------------

For the patients included in this study, the median PFS was 5.0 months (95% CI: 3.641--6.359) and median OS was 14.0 months (95% CI: 12.429--15.571) ([Figure 3](#f0015){ref-type="fig"}). There was no correlation between *BRCA* or HRD status and survival ([Figure 4](#f0020){ref-type="fig"}).Figure 3**PFS and OS rates.** OS, overall survival; PFS, progression-free survival.Figure 3Figure 4**PFS and OS according to *BRCA* status.** (A, B) PFS and (C, D) OS according to somatic *BRCA* mutation and HRD. BRCA, breast cancer susceptibility gene; HRD, homologous recombination repair deficiency; OS, overall survival; PFS, progression-free survival.Figure 4

EGFR-negative patients according to IHC tended to have a better PFS (log-rank *P* = .059) and a significantly better OS (log-rank *P* = .046) ([Figure S2](#f0030){ref-type="graphic"}). There was no correlation between the IHC status of other markers evaluated and survival.

Discussion {#s0050}
==========

In this study, we investigated correlations between response and HRD or IHC status in patients treated with the combination therapy of eribulin and olaparib in a phase the I/II trial. The combination therapy of eribulin and olaparib was well-tolerated and showed antitumor activity in patients with advanced or metastatic TNBC (response rate: 18.2%), with median PFS and median OS at 4.2 months (95% CI: 3.0--7.4) and 14.5 months (95% CI, 4.8--22.0), respectively. These findings support combination therapy with eribulin and olaparib as a promising new treatment for patients with advanced or metastatic TNBC.

Recent advances in research regarding HRD, including the use of olaparib for treating *BRCA1/2*-mutation carriers, has made HRD a potential biomarker for the treatment of TNBC. Assays that evaluate HRR capacity might help guide treatments using agents that induce or target DNA-damage repair. Niraparib is an FDA-approved PARP inhibitor used to treat ovarian cancer. In a phase-III study of niraparib, exploratory analyses were conducted in an HRD-positive subgroup, finding that the median PFS in patients with HRD-positive tumors harboring wild-type *BRCA* was longer in the niraparib group as compared with that in the placebo group [@bb0095]. Moreover, patients with HRD-positive tumors harboring a somatic *BRCA* mutation displayed similar reductions in the risk of disease progression as those observed in the cohort harboring a germline *BRCA* mutation. Additionally, niraparib treatment improved PFS in the HRD-negative subgroup.

Rucaparib is another FDA-approved PARP inhibitor that shows antitumor activity in patients with ovarian cancer. Rucaparib is approved for use in the treatment of patients with platinum-sensitive ovarian cancer and induces prolonged PSF in patients with recurrent platinum-sensitive ovarian carcinoma and who responded to platinum-based therapy associated with HRD [@bb0125]. In the present study, the ORR and CBR for the 32-patient cohort were 34.5% and 75.9%, respectively, and the frequency of nonsynonymous mutations was 100%, with the most common nonsynonymous mutation in *TP53*. These observed rates were higher than those previously reported [@bb0130]. Additionally, the frequency of gene amplification in the patients was 48.3%, with the most frequent being *MYC*. Moreover, we investigated correlations between HRD-related gene mutations and response rate to eribulin/olaparib combination therapy, finding that the ORR was numerically higher in the HRD group, although the difference was not statistically significant, and the CBR was similar between the HRD and non-HRD groups. This suggested that HRD might represent a potential biomarker for predicting the efficacy of combination therapy using olaparib with eribulin in TNBC patients.

In a previous study of combination therapy with carboplatin and eribulin in a neo-adjuvant setting, the pathological complete response (pCR) rate in *BRCA1/2*-mutation-positive patients was 66% (2/3 patients), and patients with HRD achieved higher pCR rates than non-HRD patients [@bb0135]. These data agreed with our results. Although phase-III studies of eribulin monotherapy [@bb0015], [@bb0140] and phase-I/II studies of monotherapy or combined therapy with eribulin have been reported [@bb0145], [@bb0150], [@bb0155], [@bb0160], there were data describing associated gene alterations.

The only report focusing on predictive factors in the efficacy of eribulin involved a pooled analysis of two phase-III trials [@bb0165]. One of the suspected mechanisms of eribulin action involves activity in the tumor microenvironment. Abnormal tumor vasculature leads to tumor aggressiveness, and eribulin induces the remodeling of abnormal tumor vasculature and eliminates inner tumor hypoxia [@bb0170], [@bb0175], [@bb0180]. Another possible mechanism involves suppression of the epithelial--mesenchymal transition (EMT). An *in vivo* xenograft model showed that eribulin treatment reverses EMT and induces mesenchymal--epithelial transition, and surviving TNBC cells pretreated *in vitro* with eribulin for 7 days displayed decreased lung metastasis when assessed in an *in vivo* experimental metastasis model [@bb0175], [@bb0180]. Tumor-infiltrating lymphocytes are also expected to be useful as predictive markers for eribulin efficacy during the treatment of patients with TNBC [@bb0185], and another study suggests that immune system status might correlate with eribulin efficacy [@bb0190].

In our study, EGFR-positive patients according to IHC tended to have a worse PFS and a significantly worse OS. EGFR-positivity has been reported as a prognostic factor of breast cancer [@bb0195]. But in in context of predicting efficacy of combination therapy of eribulin and olaparib, the importance of EGFR-positivity is unclear.

In conclusion, we investigated the status of epithelial and mesenchymal markers by IHC in response to combined eribulin/olaparib combination therapy. Our results showed that EGFR status was associated with better PFS and OS. The suspected mechanism associated with these results involved suppression of EMT by eribulin. Our findings also suggest that somatic *BRCA* mutations might serve as potential biomarkers for predicting the efficacy of combination therapy with eribulin and olaparib in patients with TNBC. Further analysis using a larger cohort is needed.

The following are the supplementary data related to this article.Supplementary Figure S1**IHC analysis of cancer-marker status**. (A) BRCA1 retained, (B) equivocal, and (C) loss. (D) BRCA2 retained, (E) equivocal, and (F) loss. (G) CK5/6-positive and (H) -negative. (I) E-cadherin diffuse positive, (J) focal positive, and (K) -negative. (L) EGFR 3+, (M) EGFR 2+, (N) EGFR 1+, and (O) EGFR 0. (P) Vimentin diffuse positive, (Q) focal positive, and (R) loss. (S) ZEB1-positive and (T) -negative.BRCA1, breast cancer susceptibility gene 1; BRCA2, breast cancer susceptibility gene 2; CK5/6, cytokeratin 5/6; EGFR, epidermal growth factor receptor; IHC, immunohistochemical; ZEB1, zinc finger E-box binding homeoboxSupplementary Figure S1Supplementary Figure S2**PFS and OS according to EGFR status.** (A) PFS and (B) OS according to IHC status of EGFR.EGFR, epidermal growth factor receptor; IHC, immunohistochemical; OS, overall survival; PFS, progression-free survival.Supplementary Figure S2Supplementary Table S1Antibodies used for immunohistochemistry in the present studySupplementary Table S1
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[^1]: pos: positive, neg: negative.

[^2]: chi-Square test.

[^3]: pos: positive, neg: negative.

[^4]: chi-square test.
